3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
Cyclophosphamide
10
fludarabine
8
Mycophenolic Acid
7
Tacrolimus
6
Melphalan
6
ruxolitinib
5
fludarabine phosphate
5
Imatinib Mesylate
5
Busulfan
5
Bone Marrow Transplantation
5
ponatinib
4
Mesna
4
Azacitidine
4
nilotinib
3
Whole-Body Irradiation
3
Thiotepa
3
Stem Cell Transplantation
3
Granulocyte Colony-Stimulating Factor
3
Cyclosporine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
lintuzumab
2
Vorinostat
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methotrexate
2
Filgrastim
2
Alemtuzumab
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
vosaroxin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Clinical Laboratory Techniques
×
Myeloid
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled